Scholarlink

Purpose <p>To describe the long-term auxological response to recombinant human growth hormone (rhGH) therapy in a patient with genetically confirmed Wolf–Hirschhorn syndrome (WHS) and concurrent growth hormone deficiency (GHD).</p> Methods <p>A male pediatric patient with genetically confirmed Wolf–Hirschhorn syndrome underwent comprehensive endocrine evaluation. Growth hormone stimulation testing revealed partial GHD. He subsequently received rhGH therapy for 11 years, with follow-up every 6 months including auxological measurements, biochemical assessments, and bone age determination.</p> Results <p>Across 11 years of rhGH, height improved from ~ − 4.2 to ~ − 1.3 SDS with normalized height velocity and a prolonged but uneventful pubertal course. No major adverse effects were observed. Muscle tone improvement was also noted with treatment initiation.</p> Conclusion <p>To our knowledge, this is the first documented case of a male patient with WHS and confirmed GHD who received long-term rhGH therapy, resulting in marked improvement in growth. These findings underscore the importance of routine endocrine screening for GHD in WHS. Furthermore, rhGH therapy may provide benefits beyond linear growth, potentially improving hypotonia. However, additional studies are needed to substantiate this effect.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Wolf–Hirschhorn syndrome with growth hormone deficiency: long-term response to RhGH therapy

  • 期刊论文

  • 发表日期：

    2025年9月29日

查看全文
  • Sokratis Katsoudas,
  • Evangelia Tsitsekli,
  • Ioannis Pichlinski,
  • Nikolitsa Techlemetzi,
  • Ioulia Polychroni,
  • Despoina Koumpagioti,
  • Filia Dimitriadi

摘要

Purpose

To describe the long-term auxological response to recombinant human growth hormone (rhGH) therapy in a patient with genetically confirmed Wolf–Hirschhorn syndrome (WHS) and concurrent growth hormone deficiency (GHD).

Methods

A male pediatric patient with genetically confirmed Wolf–Hirschhorn syndrome underwent comprehensive endocrine evaluation. Growth hormone stimulation testing revealed partial GHD. He subsequently received rhGH therapy for 11 years, with follow-up every 6 months including auxological measurements, biochemical assessments, and bone age determination.

Results

Across 11 years of rhGH, height improved from ~ − 4.2 to ~ − 1.3 SDS with normalized height velocity and a prolonged but uneventful pubertal course. No major adverse effects were observed. Muscle tone improvement was also noted with treatment initiation.

Conclusion

To our knowledge, this is the first documented case of a male patient with WHS and confirmed GHD who received long-term rhGH therapy, resulting in marked improvement in growth. These findings underscore the importance of routine endocrine screening for GHD in WHS. Furthermore, rhGH therapy may provide benefits beyond linear growth, potentially improving hypotonia. However, additional studies are needed to substantiate this effect.